EYEN vs. BOLT, VYNE, CARA, UNCY, NXTC, LEXX, SNSE, NBRV, DRRX, and JAN
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Bolt Biotherapeutics (BOLT), VYNE Therapeutics (VYNE), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), NextCure (NXTC), Lexaria Bioscience (LEXX), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), DURECT (DRRX), and JanOne (JAN). These companies are all part of the "pharmaceutical preparations" industry.
Bolt Biotherapeutics (NASDAQ:BOLT) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
Bolt Biotherapeutics presently has a consensus target price of $7.00, indicating a potential upside of 430.30%. Eyenovia has a consensus target price of $10.00, indicating a potential upside of 1,110.21%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Eyenovia is more favorable than Bolt Biotherapeutics.
Eyenovia has lower revenue, but higher earnings than Bolt Biotherapeutics. Eyenovia is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 4 articles in the media. Eyenovia's average media sentiment score of 1.26 beat Bolt Biotherapeutics' score of 0.28 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.
Bolt Biotherapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.
Eyenovia received 89 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 65.00% of users gave Eyenovia an outperform vote.
Eyenovia has a net margin of 0.00% compared to Eyenovia's net margin of -878.58%. Eyenovia's return on equity of -51.18% beat Bolt Biotherapeutics' return on equity.
86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 28.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Bolt Biotherapeutics beats Eyenovia on 8 of the 15 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
